These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24707992)

  • 1. Regorafenib-induced hyperammonemic encephalopathy.
    Kuo JC; Parakh S; Yip D
    J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.
    Quirino M; Rossi S; Schinzari G; Basso M; Strippoli A; Cassano A; Barone C
    Medicine (Baltimore); 2017 Apr; 96(16):e6522. PubMed ID: 28422839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose regorafenib-induced hypertensive crisis.
    Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
    Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
    Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
    Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
    Kongsuphon N; Soukavanitch M; Teeraaumpornpunt N; Konmun J; Ativitavas T; Ngamphaiboon N
    J Gastrointest Cancer; 2019 Sep; 50(3):601-603. PubMed ID: 29411249
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report.
    Akamine T; Ando K; Oki E; Saeki H; Nakashima Y; Imamura YU; Ohgaki K; Maehara Y
    Anticancer Res; 2015 Jul; 35(7):4037-41. PubMed ID: 26124352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
    Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
    Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example.
    García-Díaz HC; Eremiev S; Gómez-Alonso J; Veas Rodriguez J; Farriols A; Carreras MJ; Serrano C
    J Oncol Pharm Pract; 2024 Apr; 30(3):576-583. PubMed ID: 38258317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T
    Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
    Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
    Chan SL; Ma BB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
    Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.